Autolomous and Cellular Origins have integrated their manufacturing platforms to provide end-to-end automation and digital orchestration for cell therapy manufacturing, aiming to improve scalability, traceability and process control.

The collaboration combines Cellular Origins’ Constellation automation platform with Autolomous’ autoloMATE digital manufacturing platform, creating a connected manufacturing environment that enables data exchange across manufacturing equipment, software and robotic systems.

The companies said the integrated platform is designed to help cell therapy developers standardise manufacturing processes while supporting commercial-scale production without replacing existing manufacturing infrastructure.

Cell therapy manufacturing remains one of the sector’s biggest challenges, with developers seeking ways to automate complex, labour-intensive production while maintaining product quality and regulatory compliance as therapies move from clinical development to commercial manufacture.

The first integrations have already been completed at the Cell and Gene Therapy Catapult Digital and Automation Testbeds through an InnovateUK-funded project.

Alexander Seyf, chief executive officer of Autolomous, said: “Scientific ambition has never been the bottleneck in bringing innovative cell therapy to patients, but the delivery infrastructure has brought many challenges.

“Together with Cellular Origins, we enable fast and efficient scaling from research through to patient administration, ensuring standardisation, automation and digitisation across the entire process.”

Constellation uses mobile robotics together with existing bioprocessing technologies and sterile fluid transfer systems to automate cell therapy manufacturing. Its modular design allows manufacturers to expand production capacity without redesigning manufacturing processes.

AutoloMATE provides digital integration across manufacturing software, artificial intelligence systems, laboratory devices and robotic platforms, enabling real-time data exchange throughout manufacturing and the wider supply chain.

According to the companies, combining the two platforms addresses fragmented manufacturing systems and improves interoperability between existing technologies while maintaining protection of proprietary manufacturing data.

Edwin Stone, chief executive officer of Cellular Origins, said: “Scaling cell therapy manufacturing is not just a question of employing automation; it requires a manufacturing system that can evolve with demand. Our collaboration with Autolomous – and joint work with the Cell and Gene Therapy Catapult – clearly demonstrates how robotic platforms and digital infrastructure can operate as one.”

Demand for automated manufacturing platforms continues to increase as more cell therapies progress towards commercialisation. Developers are seeking technologies that improve manufacturing consistency, reduce manual intervention and support larger-scale production while maintaining the quality standards required for personalised therapies.

The companies said the integrated platform is intended to provide developers with greater visibility across manufacturing operations while reducing the complexity of scaling advanced therapy production.